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Background: Palliative irradiation of osteolytic lesions is a considerable component in the treatment for patients
with multiple myeloma. In this study, we analyzed the efficacy of irradiation in these patients.
Patients and methods: We retrospectively analyzed 153 patients with multiple myeloma who were admitted to
our department between 1989 and 2013. According to the staging system of Durie & Salmon 116 patients were
classified as stage III. 107/153 patients were treated with radiotherapy of at least one and up to 6 bony lesions at
different times. In order to evaluate the effect of local radiotherapy on pain relief and bone recalcification a uni- and
multivariate analysis was performed using a binary logistic regression model to correct for multiple measurements.
Complete information on dose, fractionation and volume of radiotherapy was available from 81 patients treated in 136
target volumes for pain relief, and from 69 patients treated in 108 target volumes for recalcification. Total radiation
doses varied between 8 Gy to 50 Gy (median dose 25 Gy in 2.5 Gy fractions, 5 times a week).
Results: Radiotherapy resulted in complete local pain relief in 31% and partial local pain relief in 54% of the patients. In
the univariate analysis, higher total radiation doses (p = 0.023) and higher age (p = 0.014) at the time of radiotherapy
were significantly associated with a higher likelihood of pain relief, whereas no significant association was detected for
concurrent systemic treatment, type and stage of myeloma and location of bone lesions. The same variables were
independent predictors for pain relief in the multivariate analysis. Recalcification was observed in 48% of irradiated
bone lesions. In the uni- and multivariate analysis higher radiation doses were significantly associated (p = 0.048) with
an increased likelihood of recalcification. Side effects of radiotherapy were generally mild.
Conclusions: Higher total biological radiation doses were associated with better pain relief and recalcification in this
retrospective evaluation of multiple myeloma patients. In addition, in the elderly the therapeutic measures appear to
develop a better analgesic effect.
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Table 1 Patients’ characteristics
Characteristics N
Irradiation Irradiated Pat. 107 (70%)
Target Vol. 202
No Radiation 46 (30%)
Status Alive 77 (50%)
Sex Male 86 (56%)
Female 67 (44%)
Age (years) Range 30-87 59 median
Classification IgG kappa 59 (39%)
IgG lambda 25 (16%)
IgA kappa 21 (14%)




Stage at first diagnosis I 21 (14%)
(Durie&Salmon [8]) II 16 (10%)
III A 99 (65 %)
III B 17 (11%)











Surgical intervention 29 (20)
n = number of patients, Stage = Durie and Salmon.
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Multiple myeloma is a cancer of plasma cells, clinically
characterized by recurrent bone pain, soft tissue masses,
anemia, infections, neurological symptoms, hypercalce-
mia and renal failure. Modern treatment of multiple
myeloma consists of a combination of different treat-
ment approaches including high-dose chemotherapy
followed by autologous stem cell transplantation, immu-
nomodulatory drugs, such as thalidomide, lenalidomide,
pomalidomide and proteasome inhibitors, such as borte-
zomib, carfilzomib or MLN9708. With these novel com-
binations the median overall survival of patients with
multiple myeloma approaches 50% and better, 10 years
after first diagnosis [1]. Although these are rare tumors
they are the major causes of bone involvement [2].
Osteolytic process leads to an increased risk of patho-
logic fracture and severe pain with negative impact on
quality of life.
Palliative irradiation of painful osteolytic processes is
an important component in the treatment of multiple
myeloma [3]. The efficacy of different radiation regimens
in the palliative treatment of bone metastases from solid
tumors has been tested in a number of trials [4-7]. In
some trials a small number of patients with multiple
myeloma were included, but in most cases no subgroup
analysis was presented [7]. As a consequence, different
consultants used different radiation regimens ranging
from 1×8 Gy to 20×2 Gy in the palliative treatment of
painful bone lesions and in patients with multiple mye-
loma. In our retrospective study, we analyzed the effects
of these different radiation regimes on pain relief and
recalcification.
Materials and methods
We retrospectively collected data from the records of pa-
tients with the diagnosis of multiple myeloma treated by
the Departments of Radiation Oncology and Hemato-
Oncology at the Heinrich-Heine-University in Düsseldorf,
Germany, from 1989 to 2013. Patients were excluded, if
their documentation lacked accurate information or they
suffered from another acutely life threatening neoplasm.
153 patients were identified of whom 107 underwent
radiotherapy and of whom 46 patients did not receive
radiotherapy at any time. Patients’ characteristics are dis-
played in Tables 1 and 2. Complete information on dose,
fractionation and volume of radiotherapy was available in
99 patients. Patients were followed until 2013. For the end
point pain relief after radiotherapy, valid data from 81 pa-
tients treated in 136 targeted volumes were available (1–6
target volumes per patient, median: 1 volume). For the
end point recalcification after radiotherapy, valid data of
69 patients treated in 108 targeted volumes were available
(1–5 target volumes per patient, median: 1 volume). Frac-
tionated radiotherapy was administered in 4–5 fractionsper week. Most target volumes were irradiated with 6–25
MV photons; a minority of 29 target volumes was treated
with a cobalt-60 device. External beam radiation was de-
livered via one to three or greater external beams. Indica-
tions for radiotherapy were osseous pain, pathologic
fractures, or neurological symptoms related to osteolytic
lesions. On average, radiotherapy was performed 4 months
after initial diagnosis, ranging from 1 to 179 months. Sys-
temic therapy was given simultaneously to 108 of the irra-
diated patients (Table 1). Surgical intervention in the area
of irradiation was performed in 46 patients (19 at periph-
eral fractures and 27 vertebral operations, e.g. 9 vertebro-
plastics, 11 laminectomies and 7 other procedures). The
follow-up was 1 up to 22 years after completing radiother-
apy treatment in different time intervals.
Analgesic effects during the first year after radiother-
apy were retrospectively extracted from the patient’s files
using a Likert scale [9] for pain. The analgesic effect was
Table 2 Anatomic location of irradiated osteolyses
Location Analgesia % Side Effects %
No. Total Full Partial (Level I-II)
Spine Thoracic Spine (TS) 32 84 38 47 20
Lumbar Spine (LS) 12 100 25 75 25
Cervical Spine (CS) 8 75 38 37 13
CS/TS 4 100 100 0 0
TS/LS 11 79 45 54 20
Extremities Superior 12 91 16 75 16
Inferior 15 80 0 80 8
Trunk Pelvis/Hip 24 87 41 45 19
Others Sternum 3 100 10 90 25
Ribs 9 55 11 44 11
Clivus 2 100 50 50 0
Skull 10 70 10 60 50
Extramedullary tumor 10 90 30 60 21
Other tocations/missing data 18
Level (RTOG).
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and no pain relief. For the statistical analysis a binary
outcome was used taking together partial to complete
pain relief to one category.
Recalcification was based on assessment of tumor remis-
sion by World Health Organization (WHO) criteria and di-
vided into 4 categories of skeletal metastases [10]: complete
remission (CR, for at least 4 weeks), partial remission (PR,
size reduction and recalcification), no change (status idem),
and progressive disease (PD), which was defined as a size
increase of more than 20% [11]. Recalcification was mea-
sured with the help of a computed tomography (CT) [12].
Degree of recalcification was based on a comparison of
pre-treatment and post-treatment (at least 3 months to
1 year after irradiation) radiographs (CT and/or MRI) using
ROI (Region Of Interest) and diameter measurement, as
well as manifest sclerosis. For the statistical analysis a bin-
ary outcome was used taking partial to complete remission
to one category and no change and progression to the
other category.
In addition, available information in radiation related
side effects were recorded and categorized by the criteria
of Radiation Therapy Oncology Group (RTOG) [13].
Overall survival was also assessed up to the year of 2013
for all patients.
Statistical analysis
For statistical analysis, SPSS 21.0 was used. Frequencies
were determined by descriptive analyses. P-values <0.05
were regarded as statistically significant. Overall survival
was estimated by the Kaplan-Meier method and differ-
ences of subgroups were tested by the log-rank test.In irradiated patients, the effects of radiotherapy on
the end points pain relief and recalcification were
assessed by using an uni- and multivariate binary logistic
regression model that incorporates adjustments for re-
peated measurements in the same patient (GENLIN pro-
cedure, SPSS 21.0). Radiation dose and fractionation was
normalized according to the linear quadratic model [14]
assuming no relevant repopulation to 2 Gy equivalence
doses for α/β-values of 2 Gy and 10 Gy. The Wald test
was employed to assess the significance of tested vari-
ables and for exclusion from the model in the stepwise
backward procedure in the multivariate analysis. Since
2 Gy equivalence doses using α/β-values of 2 Gy and
10 Gy were highly co-correlated, the initial model of the
multivariate analysis included the 2 Gy equivalence dose
using an α/β-values 10 Gy as dose variable only, which
was the better predictor of dose response for both end
points (pain relief and recalcification).
Results
Analgesia
Treatment-related analgesia occurred during or at the
end of the course of radiotherapy. In follow-up records
we noticed pain relief in 85% of the patients which lasted
for at least 1 year after radiotherapy. We evaluated 136
target volumes in 81 patients in terms of analgesia. In
85% of the treated patients, an analgesic effect was
achieved by irradiation of painful areas. Patients re-
ported complete and partial pain relief in 31% and 54%
of the treated lesions, respectively (no change = 12%,
progression = 3%). In the uni- and multivariate binary lo-
gistic regression analysis improved pain relief (complete/
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2 Gy-equivalence doses (α/β = 10 Gy) and higher pa-
tient’s age at the time of radiotherapy, whereas all other
tested factors were not associated with pain relief
(Table 3). According to the model, an increase from 20
to 30 Gy total dose (2 Gy equivalence (α/β = 10 Gy) re-
sulted in a 12% higher likelihood of complete or partial
pain relief (Figure 1). Also, a 70 year old patient showed a
13% greater chance of complete or partial pain relief after
radiotherapy compared to a 50 year old patient (Figure 2).
Furthermore we found no correlation between pain relief
and recalcification (Chi square test, p = 0.35).
Recalcification
The effect of radiotherapy in 108 target volumes of 69 pa-
tients were evaluated for change in calcification based on
pre- and post-treatment radiographs. Overall, recalcifica-
tion was observed in 48% of the treated bone lesions. In
23% of cases full recalcification and in 25% partial recalci-
fication was observed. No change of calcification could be
documented in 42% of the bone lesions, and 10% of the
patients developed progression of osteolytic lesions. In the
uni- and multivariate binary logistic regression analysis
higher total (2 Gy-equivalence) doses (α/β = 10 Gy) were
significantly associated with better recalcification
(complete/partial), whereas all other tested factors were
not associated with better recalcification (Tables 2,3,4).
According to the model, an increase from 20 to 30 GyTable 3 Univariate and multivariate analysis of analgesic effe
End point Variable Exp (B)
Pain relief α/β =2 Gy 1.072
Pain relief α/β =10 Gy 1.087
Pain relief target volume 1.088
Pain relief age at RT 1.062
Pain relief gender 1.432
Pain relief Typ kappa 2.572
Pain relief Typ lambda 0.360
Pain relief IgG 1.228
Pain relief IgA 1.91
Pain relief concurrent systemic treatment (yes/no) 1.285
Recalcification α/β =2 Gy 1.043
Recalcification α/β =10 Gy 1.050
Recalcification target volume 1.049
Recalcification age at RT 1.023
Multivariate analysis
Pain relief α/β =10 Gy 1.087
Pain relief age at RT 1.066
Recalcification α/β =10 Gy 1.050
CL Confidence Level, *significance.
Univariate Analysis.total dose (2 Gy equivalence dose, α/β = 10 Gy) resulted in
a 12% higher likelihood (p = 0.048) of complete or partial
recalcification (Figure 3).
Side effects
In this retrospectively evaluated cohort, 40 of 107 pa-
tients (37%) suffered from side effects related to radio-
therapy. Of these, 50% showed grade 1, and 47.2% grade
2 side effects. One patient suffered from dysphagia
(grade 3 adverse event). No case of radiation induced
myelopathy was observed clinically.
Survival
Median overall survival was 89.1 months for the whole co-
hort. Patients requiring palliative radiotherapy for painful
bone involvement had a worse prognosis than patients
without these findings (Figure 4) (median survival time 77




Osteolytic lesions and bone pain is a common symptom
in patients with multiple myeloma and present at the
time of first diagnosis in 70% of cases [5]. Larger osteo-
lytic lesions are frequently associated with pain and the
risk of fracture. Accordingly, radiotherapy in addition to
systemic treatment is typically administered in thesect and recalcification of patients undergoing radiotherapy


















Figure 1 Binary logistic regression analysis of dose effects on pain
relief (α/β= 10 Gy, p =0.023. Dotted lines indicate the 95% confidence
limits of the regression line. Tick marks indicate the number of events
(0 or 1) at the respective dose.
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relief. Bone disease remains complex and is caused by
the production of the osteoclast stimulating enzymes
[15]. The inhibition of pain mediators and the shrinkage
of the tumor are thought to be the main mechanisms of
analgesic effects derived from irradiation. The often
rapid analgesic effect of irradiation is not completelyFigure 2 Binary logistic regression analysis of age at 1st.
radiotherapy on pain relief (α/β = 10 Gy, p = 0.014. Dotted lines
indicate the 95% confidence limits of the regression line. Tick marks
indicate the number of events (0 or 1) at the respective dose.understood. Since ionizing irradiation induces apoptosis
in myeloma cells within 72 h [16], rapid death of mye-
loma cells resulting in decompression of nerves and
pressure sensors following tumor shrinkage is probably
the most important mechanism. Other proposed mecha-
nisms include the obstruction of the secretion of media-
tors such as substance P and cytokines, at the interface
of myeloma cells and the bone matrix [17,18]. Recalcifi-
cation is achieved long term after a few months, while
an analgesic effect is obtained during or immediately
after radiotherapy.
The analgesic success rate of radiotherapy in our study
was 85% of all irradiations. In the period of aftercare,
54% of our patients achieved partial analgesic effect and
31% achieved complete pain relief. Even partial pain relief
is appropriate in view of the few side effects of radiother-
apy. Uni- and multivariate logistic regression analysis re-
vealed significant better pain relief at increased (2 Gy
equivalence) total dose (α/β = 10 Gy, Figure 1) and with
increasing age at time of radiotherapy (Figure 2). Using a
α/β of 10 Gy to calculate 2 Gy equivalent total doses re-
sulted in steeper dose response curves than using a α/β of
2 Gy for calculation indirectly indicating that pain relief
behaves radiobiologically like an acute effect.
The high efficacy of radiotherapy that induces
complete or partial pain relief in 75-95% of patients with
painful myeloma bone lesions has been reported from
several independent retrospective evaluations [7,19,20].
The majority of the patients in these investigations were
treated with total doses between 30 and 40 Gy, typically
using fraction sizes between 2 and 3 Gy. Relatively few
patients were treated with low doses like 1×8 Gy or 5×4
Gy. With a few exceptions, investigators did not test
whether greater radiation doses are associated with im-
proved pain control, either because of too small vari-
ation in the employed radiation schedules or because of
too short variation in pain control. Stölting et al. found
in a univariate analysis significantly better pain control
for total doses between 40–49.9 Gy compared to total
doses below 30 Gy as well as for doses per fraction of
2 Gy compared to doses per fraction of ≥4 Gy. In the
multivariate analysis, only the use of 2 Gy per fraction
compared to doses per fraction of ≥4 Gy remained sig-
nificant. Since 2 Gy per fraction schedules were highly
associated with total doses of 40 Gy or greater, the re-
ported results can be interpreted as evidence for a sig-
nificant dose response relationship. Unfortunately, the
authors did not normalize their different fractionation
schedule by using 2 Gy equivalent dose or normalized
total doses, making a direct comparison to the data pre-
sented here difficult. Leigh et al. [21] reported a slight
trend to higher rates of pain relief at higher radiation
doses, but did also not employ a normalization of the
used fractionation schedule. In the work of Adamietz





Analgesia Simultaneous Chemotherapy Yes 73 64 87.7%
No 66 55 83.3%
Surgical Intervention Yes 20 16 80.0%
No 119 103 86.6%
Remineralization Simultaneous Chemotherapy Yes 65 29 44.6%
No 44 26 59.1%
Surgical Yes 19 07 36.8%
Intervention No 90 48 53.3%
n = number of patients.
Figure 4 Kaplan-Meier Curves; RT = 0, for patients not treated
by radiotherapy and RT = 1, for patients treated with
radiotherapy, p = 0.233.
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ized) of responding and not responding myeloma pa-
tients in terms of pain relief were identical, indirectly
indicating no distinct dose response relationship.
Whether the use of normalized total doses and more ad-
vanced statistical tools would have led to the detection
of significant dose response relationships for pain con-
trol, however, remains unclear. In view of the retrospect-
ive nature of the data presented here and the relatively
small number of patients treated with normalized total
doses below 20 Gy, the question, which dose and frac-
tionation is most appropriate for painful bone lesions
from multiple myeloma remains unresolved. Addition-
ally, all patients included in our analysis received anti-
osteoclastic drugs such as bisphosphonates as well asFigure 3 Binary logistic regression analysis of dose effects on
recalcification (α/β = 10 Gy, p = 0.048. Dotted lines indicate the
95% confidence limits of the regression line. Tick marks indicate the
number of events (0 or 1) at the respective dose.analgetics, if necessary The associated effects of these
treatments are difficult to account for given their univer-
sal use. In our investigation we found no correlation be-
tween pain relief and recalcification. Adamietz et al. [8]
reported a significantly longer duration of pain control
at higher total radiation doses. No data in this regard are
available from other authors.
An unexpected finding was that higher age at radio-
therapy was associated with better pain control. This is
in contradiction to the results of Stölting et al. [7], who
reported better outcome in patients <60 years compared
to patients >70 years. Using the same dichotomous cat-
egories instead of age as continuous variable, we found
no age effect in our cohort (data not shown). The con-
siderably younger average age in the cohort presents
here may explain the different findings that otherwise re-
main unexplained. Probably the analgesic effect is a
summation of the previous treatment, which depends on
the biology of the tumor and the prior chemotherapy.
The effect of systemic treatments on pain relief in pa-
tients with ostelytic bone lesion has not been well inves-
tigated. The shape of the dose response curve for
radiotherapy (Figure 1) suggests that approximately 50%
of patients may have the chance to experience pain relief
without radiotherapy most likely as result of the effect of
systemic treatments. Concurrent systemic therapy at the
time of radiotherapy was associated with better pain con-
trol in some reports [6]. This association was not con-
firmed in the present investigation. Since no details on
Matuschek et al. Radiation Oncology  (2015) 10:71 Page 7 of 9concurrent and sequential systemic treatments were re-
ported from any of the analyzed cohorts, potential inter-
action of radiotherapy with systemic treatments cannot be
reliably performed. However, very few severe side effects
have been reported, indicating that important interactions
of radiotherapy and systemic treatments used for the
treatment of multiple myelomas are probably rare.Recalcification
Beside pain relief, a recalcification of bony lesions is desir-
able to reduce the bone fracture rate. Therapy of solitary
plasmocytoma underline higher target volume doses are
more effective. Total doses of 45 Gy or higher in 2.0-2.5 Gy
per fraction seem to eradicate most tumors [22,23] and is
re-emphasized by studies of solid tumors [19]. But these
clinical trials do not examine multiple myeloma osteolyses
in particular.
The recalcification success rate of radiotherapy in our
study was 48% of all irradiations. During follow up, 25%
of our patients achieved partial recalcification and 23%
reached complete recalcification. Uni- and multivariate
logistic regression analysis revealed a significant better
recalcification at increased (2 Gy equivalence) total dose
(α/β = 10 Gy, Figure 3), whereas all other tested variables
were not predictive for the likelihood of recalcification
(Table 4). A limitation of our analysis is that it includes
sole radiological reports and/or ROI and diameter meas-
urement of the levels of recalcification, e.g. sclerosis,
with the help of radiographs (CT, MRI or conventional
X-ray imaging).
Recalcification after radiotherapy has been reported in
11-50% of patients with bone lesions of solid tumors
from several independent retrospective evaluations [6,7].
The majority of the patients in these investigations were
treated with total doses between 30 and 50 Gy typically
using fraction sizes between 2 and 3 Gy. Relatively few
patients were treated with low total doses like 1×8 Gy or
5×4 Gy, and most studies analyzed osteolyses of diverse
solid tumors, not just multiple myeloma patients. There







Rieden 1986 [26] 7 40-50 5X2Gy 29
Weber 1992 [27] 14 30-40 5X2Gy 71
Liebross 1998 [28] 44 30-70 5X2Gy 43
Norin 1957 [29] 53 12-48 - 51
Mose 2000 [6] 56 18-45 5X2Gy 46
Stoelting 2010 [7] 114 2-60 5X2Gy 45
Current Data 2014 108 20-60 diverse 48
n = number of patients, Gy = Gray, dose target volume.radiation doses are associated with improved recalcifica-
tion for patients with multiple myeloma.
Koswig et al. [19] examined recalcification following
radiation therapy with 2 different fractionation schedules
(1 × 8 Gy vs 10 × 3 Gy) for bone metastasis of solid tu-
mors. The recalcification showed a significant effect con-
cerning patients in the fractionated group p <0.0001). In
myeloma patients, Stölting et al. [7] found in a univariate
analysis significant better recalcification for total doses
of 50–60 Gy compared to total doses below 30 Gy. This
association remained significant in the multivariate ana-
lysis. Further significant parameters for recalcification in
the multivariate analysis were concurrent chemotherapy
vs no chemotherapy, and no fractures vs fractures. The
reported results can be interpreted as evidence for a sig-
nificant dose response relationship. Unfortunately, the
authors did not normalize total doses, making a direct
comparison to the data presented here difficult. Balducci
et al. [5] described recalcification in patients with osteo-
lytic lesions due to diverse plasma cell neoplasm in 50%
and identified as complete remission in 38%. Mose et al.
[6] also found a relevant effect in concurrent chemother-
apy, but no difference in recalcification in terms of radi-
ation dose probably due to the low variability in total
doses (30–36 Gy) (Table 5). In summary, available data
indicate that higher radiation doses result in improved
recalcification.
Side effects
Radiotherapy offers the advantage of few side effects and
therefore is an appropriate palliative procedure for treat-
ing multiple myeloma [24,25]. Our analysis found 37%
side effects with 50% grade 1, and 47.2% grade 2. One
patient suffered from dysphagia (grade 3). A substantial
increase in the side effects with simultaneous chemo-
therapy has not been reported. We found no correlation
between radiotherapy-associated side effects and overall
survival. Corresponding to us Foro and Arnalot [20] re-
ported acute side effects in 18% and Balducci et al. [5]
identified 44% of patients (n = 23) with side effects (grade
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neous toxicity in 4 (17%) patients. Mose et al. reported
about 54% side effect mostly grade 1–2; in 4 % Grade 3
(hematopoietic changes, mucositis, creatinine level).
Median overall survival was 89.1 months for the whole
cohort and radiation therapy statistically did not have an
impact on survival.
Conclusion
Palliative radiotherapy in plasma cell neoplasm’s mostly
results in pain relief without significant toxicity. Our
data indicate that higher total doses (30–36 Gy) are as-
sociated with improved pain relief. The analgesic effect
of radiotherapy in myeloma patients appears to be less
pronounced younger patients, indirectly indicating that
higher radiation doses are especially beneficial in these
patients. The likelihood of recalcification after radiother-
apy is also increased at higher total radiation doses sug-
gesting that higher doses (>40 Gy) should be considered,
if recalcification is thought to be mandatory to lower the
risk of fracture.
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